Lauren Biscaldi is the Managing Editor of Drug Topics.
Safety, Accuracy of Dexcom G7 CGM Evaluated in T1D and T2D
The CGM provides accurate readings over 10.5 days of continuous wear.
FDA Approves Expanded Indication for Adjuvant Abemaciclib in HR+/HER2- Early Breast Cancer
The expansion was based on 4-year data from the monarchE study.
Rivaroxaban Plus Aspirin Reduces Acute Limb Ischemia After Lower Extremity Revascularization in PAD
Results of an analysis of the VOYAGER PAD clinical trial were presented at ACC.23.
FDA Clears First Commercially Available Blood Test to Evaluate for TBI, Concussion
The test is intended to complement the company’s TBI plasma test, which received FDA clearance in 2021.
Register Today to Attend the Next Total Pharmacy® Solutions Summit
The Total Pharmacy® Solutions Summit will take place on April 8, 2023.
How a Bill Becomes a Law: Pharmacy Legislation to Watch
FDA Accepts Supplemental BLA For Nivolumab For Melanoma
The PDFUA date for the drug is October 13, 2023.
ASHP CEO Urges Biden Administration to Utilize Pharmacists as Care Providers in Opioid Epidemic
The letter outlined 7 steps that the Biden administration can take without the need for additional legislation.
Pharmacy Organizations Partner to Reaffirm Commitment to DEI at All Levels of Health Care
The groups released 8 recommendations to support action across the health care community.
Bills Safety Damar Hamlin Launches #3forHeart CPR Challenge
After an on-field cardiac arrest, Hamlin partnered with the American Heart Association to spotlight the importance of CPR
Prioritizing Culturally Competent Care, Advocacy, and Access in HIV
To sufficiently address HIV, stakeholders across the health care spectrum must come together.
First Adalimumab Biosimilar Launches in US Market
Adalimumab-atto was first approved by the FDA in 2016.
Breaking: FDA Committee Votes in Favor of New, Unified COVID-19 Vaccine Strategy
Recommendations from the unanimous vote must be adopted by the FDA and CDC.
Examining the Global Burden of Long COVID by Sex
Investigators analyzed the proportion of individuals with 1 of 3 clusters of Long COVID symptoms.
Bexagliflozin Approval Creates New SGLT2 Inhibitor Option for Adults With T2D
The new medication reduces HbA1c and improves glycemic control as an adjunct to diet and exercise.
DEA Joins Health Care Organizations in Applauding Repeal of X-Waiver Program
New legislation removes what many perceived as a barrier to treating opioid use disorder.
FDA Grants Priority Review Designation to OPNT003 Nasal Nalmefene for Opioid Overdose
The PDUFA date has been set for May 22, 2023.
Recommended Immunization Schedules for 2023
The updates include new recommendations for COVID-19 and pneumococcal vaccines.
Positive Topline Results Announced from Pivotal Efficacy Trial of mRNA Vaccine for RSV
Moderna’s mRNA-1345 vaccine targets RSV in older adults.
2022 Top News from Drug Topics
Take a look back at the top 15 articles that we published in 2022.
News Roundup: December 19 to December 23
Your weekly roundup of the latest news from Drug Topics®.
FDA Approves First-In-Class Twice-Yearly Treatment for HIV
Lenacapavir was approved with the FDA's Breakthrough Therapy Designation.
Help Stop the Spread of Influenza
Stay on the nice list with these tips to help stop the spread of winter respiratory viruses.
Biosimilar Uptake Increases After Changes to EHR
Biosimilar medications stand to significantly increase cost savings for patients.
2022 Pharmacy Salary Survey
Job satisfaction is down and workplace stress is on the rise.
Opioid Use in Psoriatic Arthritis Is Associated With Higher Health Care Costs, Utilization
New pathways of care are needed to improve health care spending.
Digital Therapeutics for Asthma Control May Change Treatment Paradigm
Study participants experienced better outcomes vs standard of care with a digital inhaler system.
Examining the Impact of the Roe v Wade Decision on Medication Access
Investigators set out to evaluate how medication access for certain rheumatic conditions has changed since June 2022.
Cost Savings Associated With Therapeutic Exchange of Stimulant Medications
Cost savings were not associated with an increase in adverse drug events.
Out-of-Pocket Costs Impact Medication Access for Some Medicare Beneficiaries With Schizophrenia
Low-income subsidies can eliminate much of the out-of-pocket costs that patients must pay.